uniQure N.V.
uniQure N.V. (QURE): 10 pipeline candidates · 5 upcoming catalysts · ~22 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
22.3 months
D/E 4.21 · 0% dilution
Lead: Approved
10 candidates
5 upcoming, next in ~277d
0 buys · 17 sells (180d)
A transparent, data-derived signal for uniQure N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.0B
Cash
$141.5M
Quarterly Burn
$38.2M
Runway
22.3 mo
Revenue
$3.6M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| aav9-hsyn1-migrik2 | Phase 1/Phase 2 |
| amt-130 | Phase 2 |
| amt-162 | Phase 1/Phase 2 |
| amt-191 | Phase 1/Phase 2 |
| amt-260 | Phase 1/Phase 2 |
| cetirizine hydrochloride hives | Approved |
| diclofenac | Approved |
| fexofenadine hydrochloride allergy | Approved |
| hemgenix | Approved |
| intra-striatal raav5-mihtt | Phase 1/Phase 2 |
Upcoming Catalysts (5)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
217
Total value held
$1.02B
| Holder | Shares | Value |
|---|---|---|
| susquehanna international group, llp | 3,644,200 | $59.6M |
| nantahala capital management, llc | 2,837,078 | $46.4M |
| citigroup inc | 2,811,485 | $46.0M |
| two sigma investments, lp | 2,675,871 | $43.8M |
| rtw investments, lp | 2,586,356 | $42.3M |
| caption management, llc | 2,525,231 | $41.3M |
| state street corp | 2,260,512 | $37.0M |
| orbimed advisors llc | 2,136,149 | $34.9M |
| citadel advisors llc | 1,831,065 | $29.9M |
| 683 capital management, llc | 1,753,600 | $28.7M |
Showing top 10 of 217 institutional holders of uniQure N.V.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in uniQure N.V.'s pipeline?
uniQure N.V. (QURE) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is uniQure N.V.'s lead drug candidate?
uniQure N.V.'s most advanced tracked candidate is aav9-hsyn1-migrik2 (Phase 1/Phase 2) for Mesial Temporal Lobe Epilepsy.
What is uniQure N.V.'s next catalyst?
uniQure N.V.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: DYLOJECT" — expected March 22, 2027.
What is uniQure N.V.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, uniQure N.V. has approximately 22.3 months of cash runway.
What is uniQure N.V.'s market capitalization?
uniQure N.V.'s market capitalization is approximately $3.0B.
Get the full picture on uniQure N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.